Form 4: Edgewise Therapeutics Director, Badreddin Edris, Reports Stock Option Grant
SEC Form 4 Filing
Director Badreddin Edris of Edgewise Therapeutics reports the acquisition of stock options.
Summary
- On June 12, 2024, Badreddin Edris, a director of Edgewise Therapeutics, filed a Form 4.
- The report details the acquisition of 20,594 stock options with an exercise price of $17.13 on June 10, 2024.
- These options vest on the earlier of June 10, 2025, or the business day prior to the 2025 annual meeting of stockholders and expire on June 10, 2034.
- Following the transaction, Edris directly owns 20,594 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of stock option grant and transaction. |
| 06/10/2025 | Vesting date of stock options (or earlier if the annual meeting is before this date). |
| 06/10/2034 | Expiration date of stock options. |
| 06/12/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.